OFOmar Flores

Omar Flores

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Omar Flores has a total of 183 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SARS‐CoV‐2 infections in households in a peri‐urban community of Lima, Peru: A prospective cohort study

    by Claudio F. Lanata, Ana I. Gil, Lucie Ecker, Rubelio Cornejo, Stefano Rios, Mayra Ochoa, Bia Peña, Omar Flores, Leigh M. Howard, Carlos G. Grijalva

    Background: We assessed the prevalence and incidence of SARS‐CoV‐2 infections in a prospective study of households in Lima, Peru.Methods: Households with a child, a young adult 18–50 years, and an adult age >50 years in peri‐urban Lima were followed with twice‐a‐week household visits during a 2‐month period. Nasal swabs and saliva specimens were collected twice weekly, and nasopharyngeal swabs were collected weekly from each participant, regardless of symptoms. Laboratory‐confirmed SARS‐CoV‐2 infection was defined by two RT‐PCR tests from any of the collected specimens within a week. Blood samples collected at enrollment and end of follow‐up were tested with rapid serological tests. We calculated the prevalence and incidence of laboratory‐confirmed SARS‐CoV‐2 infections.Results: We enrolled 132 participants from 44 households: 44 children, 44 young adults, and 44 older adults. A total of 13 SARS‐CoV‐2 infections were detected in eight households, for an overall period prevalence of 9.85% (95% confidence interval [CI]: 5.35–16.25). Most (61.54%) infections were symptomatic. Eight of 11 (72.73%) SARS‐CoV‐2 detections corresponded to the Lambda variant. During 218.79 person‐months at risk of follow‐up, there were six new SARS‐CoV‐2 infections detected (2.74 per 100 person‐month, 95% CI: 1.25–6.04). At enrollment, 59 of 128 participants tested had positive SARS‐CoV‐2 IgG serology (46.09%, 95% CI: 37.25–55.12). Five of six new infections occurred among participants with negative baseline serology.Conclusions: We demonstrated high incidence of SARS‐CoV‐2 infections in households, especially among subjects without evidence of prior infection, most of them not detected by the Ministry of Health system.


  • Top Cited Papers

    Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

    by Peter G Kremsner, Eunate Arana-Arri, Gustavo Jose Aroca Martinez, Marc Bonten, Reynaldo Chandler, Gonzalo Corral, Eddie Jan Louis De Block, Lucie Ecker, Julian Justin Gabor, Carlos Alberto Garcia Lopez, et al.


  • Open Access

    Desarrollo de las Vacunas contra el SARS-CoV-2 y las implicancias relacionadas a la aparición de las variantes del virus

    by Claudio F. Lanata-De Las Casas, Lucie Ecker-Ledesma, Rubelio E. Cornejo-Cotos, Carlos R. Celis-Albújar, Carmen del Pilar Díaz-Parra, Sheby A. Ricalde-Ponce de León, Omar Flores-Salmón, Mayra Ochoa Porras, Bia Peña-Peralta, Ana I. Gil-Merino

    La aparición de la pandemia causada por el virus SARS-CoV-2 tomó desprevenido al mundo entero. Sin embargo, la reacción ha sido asombrosa. En poco más de un año de la aparición del virus, se cuenta con cientos de vacunas en desarrollo y varias de ellas vienen siendo aplicadas en casi todo el mundo. En este manuscrito revisamos el estado actual del desarrollo de las vacunas, resaltando aquéllas que cuentan con estudios de Fase III (eficacia) o IV (efectividad). Además, revisamos las variantes de interés y de preocupación del virus SARS-CoV-2 detectadas hasta el momento y qué se sabe sobre de la eficacia de las vacunas contra ellas.